
REZENOPY, Highest-Dose Naloxone Nasal Spray, Enters U.S. Market
Scienture Holdings begins shipping REZENOPY, a 10mg naloxone nasal spray—the highest FDA-approved dose—bringing a new overdose reversal option as fentanyl deaths decline nationwide.
4 articles found

Scienture Holdings begins shipping REZENOPY, a 10mg naloxone nasal spray—the highest FDA-approved dose—bringing a new overdose reversal option as fentanyl deaths decline nationwide.

DyAnsys Drug Relief receives FDA clearance as a non-narcotic auricular neurostimulation device designed to alleviate opioid withdrawal symptoms during detoxification.

FDA awards priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies targeting treatment-resistant depression and PTSD.

Flow Neuroscience's transcranial direct current stimulation device becomes first prescription brain stimulation therapy available for home use, offering new option for treatment-resistant depression